$ALVR
Allovir, Inc. Stock $alvr

$alvr Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000156459021005652 Filed on February 12, 2021

Income Statement

Concept	2021 Q1	2019 Q4	2019
Revenue	$0.00		$165.0K
YoY Change			-85.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.47M		$10.62M
YoY Change	249.0%		250.5%
% of Gross Profit
Research & Development	$20.39M		$16.25M
YoY Change	198.19%		855.76%
% of Gross Profit
Depreciation & Amortization	$18.00K	$20.00K	$19.00K
YoY Change	0.0%
% of Gross Profit
Operating Expenses	$30.86M		$26.87M
YoY Change	213.65%		467.99%
Operating Profit	-$30.86M		-$26.70M
YoY Change	213.65%
Interest Expense	$510.0K		$2.070M
YoY Change	10.87%		3350.0%
% of Operating Profit
Other Income/Expense, Net	-$565.0K		$797.0K
YoY Change	-1384.09%		-28.2%
Pretax Income	-$30.92M		-$23.84M
YoY Change	231.05%		881.03%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$30.92M		-$23.84M
YoY Change	231.12%		881.03%
Net Earnings / Revenue			-14447.88%
Basic Earnings Per Share
Diluted Earnings Per Share	-$497.2K		-$344.7K
COMMON SHARES
Basic Shares Outstanding	65.11M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$337.0M	$126.1M	$126.1M
YoY Change	0.03%		468.02%
Cash & Equivalents	$168.6M	$61.08M	$61.10M
Short-Term Investments	$168.3M	$64.99M	$65.00M
Other Short-Term Assets	$2.200M		$700.0K
YoY Change	120.0%		-75.86%
Inventory
Prepaid Expenses
Receivables			$300.0K
Other Receivables			$300.0K
Total Short-Term Assets	$339.7M	$127.3M	$127.3M
YoY Change	189.32%		403.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$869.0K	$350.0K	$12.10M
YoY Change	-92.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change
Total Long-Term Assets	$11.62M	$12.11M	$12.10M
YoY Change	2.81%
TOTAL ASSETS
Total Short-Term Assets	$339.7M	$127.3M	$127.3M
Total Long-Term Assets	$11.62M	$12.11M	$12.10M
Total Assets	$351.3M	$139.4M	$139.4M
YoY Change	172.95%		450.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.057M	$630.0K	$600.0K
YoY Change	14.28%		200.0%
Accrued Expenses	$7.879M	$5.163M	$8.200M
YoY Change	45.91%		1071.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.50M	$9.106M	$9.100M
YoY Change	101.3%		145.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00		$0.00
YoY Change
Other Long-Term Liabilities	$5.400M		$8.700M
YoY Change	-31.65%
Total Long-Term Liabilities	$5.400M		$8.700M
YoY Change	-31.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.50M	$9.106M	$9.100M
Total Long-Term Liabilities	$5.400M		$8.700M
Total Liabilities	$20.91M	$17.80M	$17.80M
YoY Change	34.05%		381.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.0M	-$55.32M
YoY Change
Common Stock	$7.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$330.4M	-$51.50M	$121.6M
YoY Change
Total Liabilities & Shareholders Equity	$351.3M	$139.4M	$139.4M
YoY Change	172.95%		450.99%

Cashflow Statement

Concept	2021 Q1	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$30.92M		-$23.84M
YoY Change	231.12%		881.03%
Depreciation, Depletion And Amortization	$18.00K	$20.00K	$19.00K
YoY Change	0.0%
Cash From Operating Activities	-$18.93M	-$18.18M	-$20.16M
YoY Change	79.51%		-1138.92%
INVESTING ACTIVITIES
Capital Expenditures	$75.00K	-$340.0K	$339.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$64.90M	-$64.31M	-$64.31M
YoY Change	368.93%
Cash From Investing Activities	$64.83M	-$64.64M	-$64.64M
YoY Change	368.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		121.0M	120.9M
YoY Change			428.74%
NET CHANGE
Cash From Operating Activities	-18.93M	-18.18M	-20.16M
Cash From Investing Activities	64.83M	-64.64M	-64.64M
Cash From Financing Activities		121.0M	120.9M
Net Change In Cash	45.98M	38.13M	36.12M
YoY Change	1295.15%		45.6%
FREE CASH FLOW
Cash From Operating Activities	-$18.93M	-$18.18M	-$20.16M
Capital Expenditures	$75.00K	-$340.0K	$339.0K
Free Cash Flow	-$19.00M	-$17.84M	-$20.49M
YoY Change	80.22%		-1156.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Document Type DocumentType	10-K
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	233663000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-71309000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-26701000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2065000
CY2020	dei	Entity Registrant Name EntityRegistrantName	ALLOVIR, INC.
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001754068
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Trading Symbol TradingSymbol	ALVR
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.267
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Public Float EntityPublicFloat	1286188221.08
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65106873
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity File Number EntityFileNumber	001-39409
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1971007
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	139 Main Street
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	433-2605
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122661000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61084000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	233663000
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	64993000
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	450000
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	262000
CY2019Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	298000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4543000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	676000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	361317000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	127313000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	812000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	350000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8692000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16248000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21646000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10618000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11759000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5463000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9106000
CY2020Q4	us-gaap	Assets Assets	370821000
CY2019Q4	us-gaap	Assets Assets	139422000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	963000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	630000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7530000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5163000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3229000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3067000
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	572000
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	246000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12294000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8692000
CY2020Q4	us-gaap	Liabilities Liabilities	17757000
CY2019Q4	us-gaap	Liabilities Liabilities	17798000
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	478272000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3748000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-112000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	68000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125103000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55319000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	353064000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-51503000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	370821000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	139422000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65106873
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6502929
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61931255
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2099740
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	165000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49663000
CY2020	us-gaap	Operating Expenses OperatingExpenses	71309000
CY2019	us-gaap	Operating Expenses OperatingExpenses	26866000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1330000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	195000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	797000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-69784000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-23839000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-180000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	68000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69964000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23771000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-30622000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2890000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	291975000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.59
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-18.54
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26897390
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1285933
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-90000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	68000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-90000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	173127000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9429000
CY2020	us-gaap	Profit Loss ProfitLoss	-69784000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	291975000
CY2019	us-gaap	Profit Loss ProfitLoss	-23839000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19000
CY2020	alvr	Amortization And Accretion Of Discounts On Short Term Investments AmortizationAndAccretionOfDiscountsOnShortTermInvestments	-502000
CY2019	alvr	Amortization And Accretion Of Discounts On Short Term Investments AmortizationAndAccretionOfDiscountsOnShortTermInvestments	620000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	9429000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2890000
CY2020	alvr	Increase Decrease In Unbilled Grants Receivable IncreaseDecreaseInUnbilledGrantsReceivable	-298000
CY2019	alvr	Increase Decrease In Unbilled Grants Receivable IncreaseDecreaseInUnbilledGrantsReceivable	-4000
CY2020	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	188000
CY2019	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	262000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3867000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	620000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2726000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4936000
CY2019	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-2663000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60811000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20155000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	339000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	300262000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	119305000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	131000000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	55000000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-169497000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64644000
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	121253000
CY2019	alvr	Payments For Issuance Costs Related To Issuance Of Preferred Stock PaymentsForIssuanceCostsRelatedToIssuanceOfPreferredStock	330000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3474000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	295449000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120923000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-90000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61577000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36124000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	61084000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24960000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	122661000
CY2020	alvr	Unrealized Gain Loss On Available For Sale Securities UnrealizedGainLossOnAvailableForSaleSecurities	-90000
CY2019	alvr	Unrealized Gain Loss On Available For Sale Securities UnrealizedGainLossOnAvailableForSaleSecurities	68000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13213000
CY2020	alvr	Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	300000
CY2019	alvr	Purchase Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	30000
CY2019	alvr	Issuance Of Preferred Stock Related To Anti Dilution Rights IssuanceOfPreferredStockRelatedToAntiDilutionRights	3681000
CY2020	alvr	Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering ConversionOfPreferredStockToCommonStockUponInitialPublicOffering	173127000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	125000
CY2020	alvr	Underwriting Discounts UnderwritingDiscounts	22238000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AlloVir, Inc. (“AlloVir” or “the Company”, formerly known as ViraCyte, Inc.) is a leading late clinical-stage cell therapy company developing highly innovative allogeneic T-cell therapies to treat and prevent devastating viral diseases. The Company’s innovative and proprietary virus-specific T-cell, or VST, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T-cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. To date, the Company has generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, the most advanced for which the Company has initiated a pivotal trial for the treatment of virus-associated hemorrhagic cystitis and a proof-of-concept, or POC, clinical trial for multi-virus prevention in the fourth quarter of 2020.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s lead product candidate, Viralym-M, is a multi-VST cell therapy that targets five viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus and human herpesvirus 6. To fully explore the clinical benefit of Viralym-M, the Company plans to initiate a total of three Phase 3 pivotal and three Phase 2 proof-of-concept trials by the end of 2021 for the treatment and prevention of life-threatening viral diseases in pediatric and/or adult patients, each representing a potential meaningful commercial opportunity.  In addition, ALVR106 is the Company’s second multi-virus-targeted off-the-shelf VST product candidate targeting devastating respiratory diseases caused by RSV, influenza, PIV and/or hMPV. An Investigational New Drug, or IND, application with the <font style="color:#000000;">FDA for ALVR106 was cleared in the fourth quarter of 2020 and the Company plans to initiate a Phase 1/2 clinical study in autologous and allogeneic HSCT patients with respiratory viral diseases in the 2021-2022 respiratory virus season. Pursuant to the sponsored research agreement with Baylor College of Medicine (“BCM”), BCM initiated a proof-of-concept trial for ALVR109, an allogeneic, off-the-shelf VST therapy designed to target SARS-CoV-2, the virus that causes the severe and life-threatening viral disease, COVID-19. ALVR109 is being developed to arrest the progression of COVID-19 by eradicating SARS-CoV-2 virus-infected cells.  BCM initiated the POC clinical trial in the fourth quarter of 2020 and the trial is ongoing and actively recruiting. Lastly, the Company is advancing ALVR107 designed to target hepatitis B, or HBV, infected cells and treat chronic HBV infections and ALVR108 to treat human herpesvirus-8, or HHV-8, associated diseases including Kaposi Sarcoma, or KS, primary effusion lymphoma, or PEL, and multicentric Castleman’s disease, or MCD. The Company plans to complete pre-clinical IND enabling studies for ALVR107 and ALVR108 in the second half of 2021. </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was formed on August 16, 2013 as a Delaware limited liability company (“LLC”) under the name AdCyte LLC and on July 29, 2014 the Company changed its name to ViraCyte LLC. On September 17, 2018, the Company converted from a Delaware LLC to a Delaware corporation (“LLC Conversion”) and changed its name to ViraCyte, Inc. On May 22, 2019, the Company changed its name to AlloVir, Inc. The Company has principal offices in Houston, Texas and Cambridge, Massachusetts. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2019, AlloVir formed AlloVir International Designated Activity Company (“AlloVir International”), a wholly-owned subsidiary established in Ireland. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 9, 2019, AlloVir Securities Corporation was incorporated as a Massachusetts Security Corporation, a wholly-owned subsidiary of AlloVir. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 10, 2019, AlloVir International formed AlloVir Italia S.R.L. (“AlloVir Italia”), a wholly-owned subsidiary in Italy.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 3, 2020, the Company completed an initial public offering (“IPO”) in which the Company issued and sold 18,687,500 shares of its common stock, at a public offering price of $17.00 per share, resulting in gross proceeds of $317.7 million. The Company received $292.0 million in net proceeds after deducting underwriting discounts and commissions and offering costs. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.58%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all of the then-outstanding shares of convertible preferred stock automatically converted into 39,859,139 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ElevateBio LLC </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2018, the Company executed a Series A2 Preferred Stock Purchase Agreement (“Series A2 Agreement”) with ElevateBio, LLC, a Delaware LLC (“ElevateBio”) concurrent with the LLC Conversion. ElevateBio was formed on November 29, 2017 and is headquartered in Cambridge, Massachusetts with a focus on the development of a portfolio of novel cell therapy programs acquired through business development activities with biotechnology companies. ElevateBio is structured as a holding company, comprised of asset-specific subsidiaries focused on the development of pipeline assets, as well as a manufacturing subsidiary with the expertise to provide drug development and manufacturing services. As a result of the purchase of the Company’s Series A2 Preferred Stock, ElevateBio acquired an ownership interest in the Company (see Note 17 for further discussion). The Chief Executive Officer, Chief Financial Officer, and other executives of ElevateBio also serve in similar management roles with AlloVir.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Update (“ASU”) 2014-15,<font style="font-style:italic;"> Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</font>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.           </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2020, the Company has funded its operations primarily with proceeds received from the sale of common stock, research grants, and from the sale of preferred stock. The Company has incurred recurring losses since its inception, including net losses attributable to common stockholders of $69.8 million for the year ended December 31, 2020 and $23.8 million for the year ended December 31, 2019. In addition, at December 31, 2020, the Company had an accumulated deficit of $125.1 million. The Company expects to continue to generate operating losses for the foreseeable future. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its $122.7 million of cash and cash equivalents and $233.7 million of short-term investments held at December 31, 2020, are sufficient to fund planned operations for at least twelve months from the date that these consolidated financial statements are available to be issued. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19 Considerations </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of product candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of an infectious disease, such as the recent COVID-19 pandemic. The spread of COVID-19 has impacted the global economy and has impacted the Company’s operations, including the interruption of preclinical and clinical trial activities and potential interruption to the Company’s supply chain. For example, the COVID-19 pandemic has delayed clinical trials. If the disruption due to the COVID-19 pandemic continues, planned pivotal clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay the Company’s ability to conduct preclinical studies and clinical trials or release clinical trial results and could delay the Company’s ability to obtain regulatory approval and commercialize product candidates. Furthermore, COVID-19 could affect the Company’s employees or the employees of research sites and service providers on whom the Company relies on as well as those of companies with which the Company does business, including suppliers and contract manufacturing organizations or CMOs, thereby disrupting business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which the Company and the companies with which it does business operate could materially impact the ability of employees to access preclinical and clinical sites, laboratories, manufacturing sites and offices. The Company has implemented work-at-home policies and only employees essential to the development and research of product candidates remain on-site at the Company’s research and manufacturing facilities; accordingly, the Company may experience limitations in employee resources. The outbreak and any other preventative or protective actions that the Company, its suppliers or other third parties with which it has business relationships, or governments may take in respect of the COVID-19 pandemic, could disrupt, delay or otherwise adversely impact the business.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is still assessing business plans and the impact the COVID-19 pandemic may have on its ability to advance the testing, development and manufacturing of drug candidates, including as a result of adverse impacts on the research sites, service providers, vendors, or suppliers on whom the Company relies on, or to raise financing to support the development of our drug candidates. No assurances can be given that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or this sector in particular. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties on whom it relies on or with whom it conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct business in the manner and on the timelines presently planned could be materially and adversely impacted.</p>
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates. </p>
CY2020	alvr	Cash And Cash Equivalents Maturity Period CashAndCashEquivalentsMaturityPeriod	P3M
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M29D
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Off-Balance Sheet Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that subject the Company to credit risk consist primarily of cash, cash equivalents, restricted cash and short-term investments. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have and will continue to exceed federally insured limits. The Company has not experienced any losses on its cash deposits. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020 and 2019, the Company had no off-balance sheet risk. </p>
CY2020	alvr	Short Term Investments Maturity Period ShortTermInvestmentsMaturityPeriod	P1Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0514
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	904000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	369000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19000
CY2020	alvr	Number Of Individual Securities With Impairment NumberOfIndividualSecuritiesWithImpairment	0
CY2019	alvr	Number Of Individual Securities With Impairment NumberOfIndividualSecuritiesWithImpairment	0
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	4000000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2100000
CY2020Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	292000000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3600000
CY2020	alvr	Variable Non Lease Cost VariableNonLeaseCost	4500000
CY2019	alvr	Variable Non Lease Cost VariableNonLeaseCost	1800000
CY2020	alvr	Lease Expiration Month And Year LeaseExpirationMonthAndYear	2021-03
CY2020	us-gaap	Property Plant And Equipment Basis Of Valuation PropertyPlantAndEquipmentBasisOfValuation	cost
CY2020	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	recognizes depreciation using the straight-line method over the estimated useful lives of the respective assets
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2019Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	100000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2020	us-gaap	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk	At December 31, 2020 and 2019, the Company had no off-balance sheet risk.
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	233687000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64925000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	68000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	24000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	64993000
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	95503000
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	56434000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	400000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	300000
CY2020	alvr	Non Lease Costs Including Utilities And Cleaning NonLeaseCostsIncludingUtilitiesAndCleaning	100000
CY2019	alvr	Non Lease Costs Including Utilities And Cleaning NonLeaseCostsIncludingUtilitiesAndCleaning	43000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3600000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3600000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2100000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9300000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	608000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8692000
CY2020	us-gaap	Depreciation Depreciation	100000
CY2019	us-gaap	Depreciation Depreciation	19000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3314000
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1520000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	696000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	445000
CY2020Q4	alvr	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3347000
CY2019Q4	alvr	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3051000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	173000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	147000
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2663000
CY2019	alvr	Contract With Customer Liability Returned Payments ContractWithCustomerLiabilityReturnedPayments	2663000
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	79398350
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	59398350
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	59398350
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	173127000
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	188034000
CY2019Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	39859139
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	27.97
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2890000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-68356000
CY2020	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.08
CY2020	alvr	Number Of Votes Per Share NumberOfVotesPerShare	1
CY2020	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders (and written actions in lieu of meetings), and there are not any cumulative voting rights. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company; however, the issuance of common stock may be subject to the vote of the holders of one or more series of preferred stock that may be required by terms of the Third Amended and Restated Certificate of Incorporation.
CY2020	us-gaap	Dividends Cash DividendsCash	0
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11279849
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	44793329
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	44960
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3952949
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25000
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3972909
CY2020Q4	alvr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	20609
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.01
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.08
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.84
CY2020Q4	alvr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice	5.56
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7M6D
CY2020	alvr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm	P8Y10M24D
CY2020	alvr	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAggregateIntrinsicValue	226000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	81822000
CY2020Q4	alvr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue	678000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.77
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.17
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.84
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0036
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0165
CY2020Q4	us-gaap	Share Price SharePrice	18.08
CY2019Q4	us-gaap	Share Price SharePrice	3.01
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9429000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-23839000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1428000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-69784000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23839000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14655000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5006000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1943000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-565000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17756000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6354000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1220000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	753000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	62000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-30000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.028
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.017
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20866000
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2747000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.254
CY2020Q4	alvr	Deferred Tax Liabilities Restricted Stock Compensation DeferredTaxLiabilitiesRestrictedStockCompensation	629000
CY2019Q4	alvr	Deferred Tax Liabilities Restricted Stock Compensation DeferredTaxLiabilitiesRestrictedStockCompensation	1650000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2244000
CY2019	us-gaap	Management Fee Expense ManagementFeeExpense	400000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7604000
CY2020Q4	alvr	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	2244000
CY2019Q4	alvr	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	2747000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1326000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2215000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	753000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	910000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	183000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27561000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11287000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24555000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6799000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3006000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4488000
CY2020Q4	alvr	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	65000
CY2019Q4	alvr	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	75000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	68000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	16000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3006000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4488000
CY2020	alvr	Operating Loss Carryforwards Carryback Period OperatingLossCarryforwardsCarrybackPeriod	P5Y
CY2020	alvr	Tax Cuts And Jobs Act Of2017 Percentage Of Limitations On Net Operating Loss Carryforwards To Taxable Income TaxCutsAndJobsActOf2017PercentageOfLimitationsOnNetOperatingLossCarryforwardsToTaxableIncome	0.80
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-69784000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-23839000
CY2020	us-gaap	Long Term Purchase Commitment Minimum Quantity Required LongTermPurchaseCommitmentMinimumQuantityRequired	1
CY2020Q4	alvr	Long Term Purchase Commitment Amount Per Month LongTermPurchaseCommitmentAmountPerMonth	300000
CY2020	alvr	Long Term Purchase Commitment Expiration Month And Year LongTermPurchaseCommitmentExpirationMonthAndYear	2023-07
CY2020	us-gaap	Management Fee Expense ManagementFeeExpense	600000
CY2020	us-gaap	Defined Contribution Plan Plan Name Extensible List DefinedContributionPlanPlanNameExtensibleList	alvr:FourZeroOneKPlanMember
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000

Files In Submission

Name	View Source	Status
0001564590-21-005652-index-headers.html	Edgar Link	pending
0001564590-21-005652-index.html	Edgar Link	pending
0001564590-21-005652.txt	Edgar Link	pending
0001564590-21-005652-xbrl.zip	Edgar Link	pending
alvr-10k_20201231.htm	Edgar Link	pending
alvr-20201231.xml	Edgar Link	completed
alvr-20201231.xsd	Edgar Link	pending
alvr-20201231_cal.xml	Edgar Link	unprocessable
alvr-20201231_def.xml	Edgar Link	unprocessable
alvr-20201231_lab.xml	Edgar Link	unprocessable
alvr-20201231_pre.xml	Edgar Link	unprocessable
alvr-ex1017_627.htm	Edgar Link	pending
alvr-ex1018_1063.htm	Edgar Link	pending
alvr-ex1019_1062.htm	Edgar Link	pending
alvr-ex1020_1061.htm	Edgar Link	pending
alvr-ex231_952.htm	Edgar Link	pending
alvr-ex311_9.htm	Edgar Link	pending
alvr-ex312_8.htm	Edgar Link	pending
alvr-ex321_7.htm	Edgar Link	pending
alvr-ex322_6.htm	Edgar Link	pending
alvr-ex42_626.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gfj5i0zv1xby000001.jpg	Edgar Link	pending
gixwmmox0mqc000001.jpg	Edgar Link	pending
gixwmmox0mqc000002.jpg	Edgar Link	pending
gixwmmox0mqc000003.jpg	Edgar Link	pending
gixwmmox0mqc000004.jpg	Edgar Link	pending
gixwmmox0mqc000005.jpg	Edgar Link	pending
gixwmmox0mqc000006.jpg	Edgar Link	pending
gixwmmox0mqc000007.jpg	Edgar Link	pending
gixwmmox0mqc000008.jpg	Edgar Link	pending
gixwmmox0mqc000009.jpg	Edgar Link	pending
gixwmmox0mqc000010.jpg	Edgar Link	pending
gixwmmox0mqc000011.jpg	Edgar Link	pending
gixwmmox0mqc000012.jpg	Edgar Link	pending
gixwmmox0mqc000013.jpg	Edgar Link	pending
gixwmmox0mqc000014.jpg	Edgar Link	pending
gixwmmox0mqc000015.jpg	Edgar Link	pending
gixwmmox0mqc000016.jpg	Edgar Link	pending
gixwmmox0mqc000017.jpg	Edgar Link	pending
gixwmmox0mqc000018.jpg	Edgar Link	pending
gixwmmox0mqc000019.jpg	Edgar Link	pending
gixwmmox0mqc000020.jpg	Edgar Link	pending
gixwmmox0mqc000021.jpg	Edgar Link	pending
gixwmmox0mqc000022.jpg	Edgar Link	pending
gixwmmox0mqc000023.jpg	Edgar Link	pending
gixwmmox0mqc000024.jpg	Edgar Link	pending
gixwmmox0mqc000025.jpg	Edgar Link	pending
gixwmmox0mqc000026.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALVR
Allovir, Inc. Stock $alvr

2021 Q1 Form 10-K Financial Statement

#000156459021005652 Filed on February 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALVR Allovir, Inc. Stock $alvr

2021 Q1 Form 10-K Financial Statement

#000156459021005652 Filed on February 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALVR
Allovir, Inc. Stock $alvr